<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2681204-A1" country="EP" doc-number="2681204" kind="A1" date="20140108" family-id="46753714" file-reference-id="318301" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587062" ucid="EP-2681204-A1"><document-id><country>EP</country><doc-number>2681204</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12752121-A" is-representative="NO"><document-id mxw-id="PAPP154849254" load-source="docdb" format="epo"><country>EP</country><doc-number>12752121</doc-number><kind>A</kind><date>20120301</date><lang>EN</lang></document-id><document-id mxw-id="PAPP173226924" load-source="docdb" format="original"><country>EP</country><doc-number>12752121.9</doc-number><date>20120301</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140552110" ucid="US-201161448317-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161448317</doc-number><kind>P</kind><date>20110302</date></document-id></priority-claim><priority-claim mxw-id="PPC140549846" ucid="US-2012027234-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012027234</doc-number><kind>W</kind><date>20120301</date></document-id></priority-claim></priority-claims><dates-of-public-availability><search-report-dispatch-date><date>20131107</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989316379" load-source="docdb">C07C  45/42        20060101ALI20131101BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989317293" load-source="docdb">C07F   7/04        20060101ALI20131101BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989317328" load-source="docdb">C07C 213/08        20060101ALI20131101BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323038" load-source="docdb">C07D 315/00        20060101AFI20131101BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323340" load-source="docdb">C07F   7/08        20060101ALI20131101BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1713572098" load-source="docdb" scheme="CPC">C07C  45/68        20130101 LI20180104BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1783990967" load-source="docdb" scheme="CPC">C07F   1/08        20130101 LI20170713BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1783990968" load-source="docdb" scheme="CPC">C07C  51/00        20130101 FI20170715BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1783990969" load-source="docdb" scheme="CPC">C07C  45/42        20130101 LI20170715BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1877550947" load-source="docdb" scheme="CPC">C07C 213/08        20130101 LI20161117BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1962107283" load-source="docdb" scheme="CPC">C07C  47/575       20130101 LI20160311BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365819" lang="DE" load-source="patent-office">SYNTHESE VON ZWISCHENPRODUKTEN ZUR TREPROSTINILHERSTELLUNG</invention-title><invention-title mxw-id="PT132365820" lang="EN" load-source="patent-office">SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION</invention-title><invention-title mxw-id="PT132365821" lang="FR" load-source="patent-office">SYNTHÈSE D'UN INTERMÉDIAIRE POUR LA PRODUCTION DE TRÉPROSTINIL</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919540921" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNITED THERAPEUTICS CORP</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919544222" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>UNITED THERAPEUTICS CORPORATION</last-name></addressbook></applicant><applicant mxw-id="PPAR919006671" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>United Therapeutics Corporation</last-name><iid>101287750</iid><address><street>1040 Spring Street</street><city>Silver Spring, MD 20910</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919527830" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SHARMA VIJAY</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919545488" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SHARMA, VIJAY</last-name></addressbook></inventor><inventor mxw-id="PPAR919014911" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SHARMA, VIJAY</last-name><address><street>4837 Tothill Drive</street><city>Olney, Maryland 20832</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919015417" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Schneider, Michael</last-name><suffix>et al</suffix><iid>101160292</iid><address><street>Heisse Kursawe Eversheds Rechtsanwälte Partnerschaft Maximiliansplatz 5</street><city>80333 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012027234-W"><document-id><country>US</country><doc-number>2012027234</doc-number><kind>W</kind><date>20120301</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012118943-A1"><document-id><country>WO</country><doc-number>2012118943</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549917851" load-source="docdb">AL</country><country mxw-id="DS549864936" load-source="docdb">AT</country><country mxw-id="DS549917852" load-source="docdb">BE</country><country mxw-id="DS549768301" load-source="docdb">BG</country><country mxw-id="DS549768043" load-source="docdb">CH</country><country mxw-id="DS549850376" load-source="docdb">CY</country><country mxw-id="DS549850377" load-source="docdb">CZ</country><country mxw-id="DS549781014" load-source="docdb">DE</country><country mxw-id="DS549917853" load-source="docdb">DK</country><country mxw-id="DS549850382" load-source="docdb">EE</country><country mxw-id="DS549849057" load-source="docdb">ES</country><country mxw-id="DS549768302" load-source="docdb">FI</country><country mxw-id="DS549768303" load-source="docdb">FR</country><country mxw-id="DS549781015" load-source="docdb">GB</country><country mxw-id="DS549917854" load-source="docdb">GR</country><country mxw-id="DS549781016" load-source="docdb">HR</country><country mxw-id="DS549850383" load-source="docdb">HU</country><country mxw-id="DS549768044" load-source="docdb">IE</country><country mxw-id="DS549917855" load-source="docdb">IS</country><country mxw-id="DS549768304" load-source="docdb">IT</country><country mxw-id="DS549917856" load-source="docdb">LI</country><country mxw-id="DS549781033" load-source="docdb">LT</country><country mxw-id="DS549864937" load-source="docdb">LU</country><country mxw-id="DS549781034" load-source="docdb">LV</country><country mxw-id="DS549781035" load-source="docdb">MC</country><country mxw-id="DS549864942" load-source="docdb">MK</country><country mxw-id="DS549864943" load-source="docdb">MT</country><country mxw-id="DS549768309" load-source="docdb">NL</country><country mxw-id="DS549768053" load-source="docdb">NO</country><country mxw-id="DS549768310" load-source="docdb">PL</country><country mxw-id="DS549849062" load-source="docdb">PT</country><country mxw-id="DS549768311" load-source="docdb">RO</country><country mxw-id="DS549849063" load-source="docdb">RS</country><country mxw-id="DS549768312" load-source="docdb">SE</country><country mxw-id="DS549850690" load-source="docdb">SI</country><country mxw-id="DS549768054" load-source="docdb">SK</country><country mxw-id="DS549768055" load-source="docdb">SM</country><country mxw-id="DS549917857" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99830332" ref-ucid="WO-2012118943-A1" lang="EN" load-source="patent-office"><p num="0000">The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.</p></abstract><abstract mxw-id="PA100327160" ref-ucid="WO-2012118943-A1" lang="EN" source="national office" load-source="docdb"><p>The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.</p></abstract><abstract mxw-id="PA99830333" ref-ucid="WO-2012118943-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention fournit un procédé efficace de synthèse d'un composé de formule I, ledit composé selon la formule I étant un intermédiaire dans la synthèse d'analogues de la prostacyline.</p></abstract><abstract mxw-id="PA100327161" ref-ucid="WO-2012118943-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention fournit un procédé efficace de synthèse d'un composé de formule I, ledit composé selon la formule I étant un intermédiaire dans la synthèse d'analogues de la prostacyline.</p></abstract><description mxw-id="PDES51232196" ref-ucid="WO-2012118943-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL </p><p id="p0002" num="0002"> PRODUCTION </p><p id="p0003" num="0003">RELATED APPLICATIONS </p><p id="p0004" num="0004">The present application claims priority to US provisional application no. 61/448,317 filed March 2, 201 1 , which is incorporated herein by reference in its entirety. </p><p id="p0005" num="0005">FIELD </p><p id="p0006" num="0006">The present application relates generally to the field of pharmaceutical production and more specifically to methods of synthesizing an intermediate for producing prostacyclin derivatives, such as Treprostinil. </p><p id="p0007" num="0007">SUMMARY </p><p id="p0008" num="0008">One embodiment is a method for synthesizing a compound according to Formula I. 
<img id="imgf000002_0001" he="17" wi="19" file="imgf000002_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0009" num="0009"> According to the method, the compound of Formula I may be synthesized by hydrolyzing a compound represented by Formula A. 
<img id="imgf000002_0002" he="19" wi="38" file="imgf000002_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0010" num="0010"> For Formula A compounds, "x" may be an integer between 0 and 4 inclusive. Substituent R may be selected from the group consisting of H, straight or branched (Ci-C6)alkyl, (C6- Ci4)aryl, and (C6-C i4)aryl(Ci-C6)alkylene-, while substituent groups R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are each independently selected from the group consisting of H, straight or branched (C] -C6)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene- and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl(C<sub>r</sub> C6)alkylene-. 
<!-- EPO <DP n="3"/>-->
 In some embodiments, the hydrolysis of a Formula A compound may be accomplished by contact with water, aqueous mineral acid, or an aqueous solution of sodium sulfite. </p><p id="p0011" num="0011"> Another embodiment may be a method for synthesizing a Formula A compound. Such synthesis may be accomplished by contacting a Formula B compound with an organolithium reagent, such as phenyllithium or butyllithium to form an otho-lithiated intermediate which may be converted to a cuprate using copper cyanide. 
<img id="imgf000003_0001" he="20" wi="33" file="imgf000003_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0012" num="0012"> The obtained cuprate may be then contacted with an allyl halide, for example, with an allyl chloride, an allyl bromide, or an allyl iodide synthesize a compound according to Formula A.</p><p id="p0013" num="0013">In some embodiments, R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> may be each independently (Ci-C6)alkyl and "x" is 2. In one embodiment, R<sup>a</sup>, R<sup>b</sup> and R° are each methyl and "x" is 2. </p><p id="p0014" num="0014"> R may be an alcohol protecting group, straight or branched (Ci-C6)alkyl; (C6-Ci<sub>4</sub>)aryl and (C6-Ci<sub>4</sub>)aryl(Ci-C6)alkylene-. For example, R may be selected from methyl, ethyl, propoyl, isopropyl, butyl, iso-butyl, tert-butyl, pentyl, neo-pentyl, hexyl and branched hexyl. For example, in one embodiment substituent R may be methyl. Alternatively, R may be a (Ce- Ci )aryl(Ci-C6)alkylene-, for example a benzyl group. </p><p id="p0015" num="0015"> The allylating agent may be, for example, an allyl halide, such as an allyl bromide or an allyl iodide, although other allylating reagents may also be used. </p><p id="p0016" num="0016"> Yet another embodiment may be a method for synthesizing a Formula I compounds, which may include the following: </p><p id="p0017" num="0017"> (a) contacting an aldehyde represented by Formula C with a compound selected from the group consisting of R<sup>a</sup>-NH<sub>2</sub>, R<sup>a</sup>R<sup>b</sup>N-(CHR ' )<sub>x</sub>-NHR<sup>a</sup> and R'-OH in the presence of an organolitium; 
<img id="imgf000003_0002" he="17" wi="18" file="imgf000003_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 
<!-- EPO <DP n="4"/>-->
 (b) contacting the product from step (a) with an organolithium to form an ortho-lithiated product which is contacted with copper cyanide to form a cuprate; </p><p id="p0018" num="0018"> (c) contacting the cuprate from step (b) with an allyl halide selected from the group consisting of allyl chloride, allyl bromide and allyl iodide to form a Formula A compound which is hydrolyzed to give a Formula I compound. </p><p id="p0019" num="0019">DETAILED DESCRIPTION </p><p id="p0020" num="0020">Unless otherwise specified, "a" or "an" means one or more. </p><p id="p0021" num="0021"> (+)-Treprostinil (also known as UT-15) is the active ingredient in Remodulin®, a commercial drug approved by FDA for the treatment of pulmonary arterial hypertension (PAH). It was first described in U.S. Pat. No. 4,306.075. Treprostinil is a stable analog of prostacyclin (PGI2) belonging to a class of compounds known as benzindene prostacyclins, which are useful pharmaceutical . compounds possessing activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and bronchodilation. </p><p id="p0022" num="0022"><img id="imgf000004_0001" he="45" wi="141" file="imgf000004_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0023" num="0023"> U.S. Pat. Nos. 5,153,222, 6,054,486; 6,521 ,212; 6,756,033; 6,803,386; 7,199, 157; 7,879,909 and 7,999,007 as well as U.S. patent application publications Nos. 2005/01651 1 1 ; </p><p id="p0024" num="0024">2008/0200449; 2008/0280986; 2009/0124697; 2009/0281 189; 2009/0036465; </p><p id="p0025" num="0025">2010/0076083; 2010/0282622; 201 1/0092599; 201 1/0144204; 201 1/0224236; 2012/0004307 and 2012/0010159 disclose various applications of treprostinil. U.S. Pat. Nos. 7,417,070, 7,384,978 and 7,544,713 as well as U.S. publications Nos. 2005/0282901 ; 2007/0078095; 2008/0249167 and 201 1/01 18213 describe oral formulations of treprostinil and other prostacyclin analogs as well as their use for treatment of a variety of conditions. 
<!-- EPO <DP n="5"/>-->
 The following documents provide information, which may be useful for preparing treprostinil and/or other prostacyclin derivatives: Moriarty, et al in J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001 , 26(4), 364-374, Aristoff et al. JACS 107(26), 1985, 7967-74; Aristoff et al. Advances in Prostaglandin, Thromboxane and Leukotriene Research, vol. 1 1 , 267, 1983; U.S. Pat. Nos. 4,306,075, 4,668,814; 4,683,330; 6,441 ,245, 6,528,688, 6,700,025, 6,765,1 17, 6,809,223; US Publications Nos. 2009/0163738 and 201 1/0319641 as well as PCT publication WO2012009816. </p><p id="p0026" num="0026"> A compound of Formula I may be a key intermediate in the syntheses of (+) Treprostinil and other prostacyclin derivatives, such as the ones disclosed in US patents nos. 6,441 ,245, 6,528,688, 6,700,025, 6,765,1 17, 6,809,223 and US Publications Nos. 2009/0163738 and 201 1/0319641 as well as PCT publication WO2012009816: </p><p id="p0027" num="0027"><img id="imgf000005_0001" he="22" wi="25" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0028" num="0028"> The present inventor developed a novel method for synthesizing a Formula I compound. Specifically, the inventor provide a synthesis for Formula I compounds, which may be performed efficiently in one pot using commercially available starting materials. </p><p id="p0029" num="0029"> Definitions </p><p id="p0030" num="0030"> In the context of the present invention, "alkyl" refers to straight, branched chain, or cyclic hydrocarbyl groups including from 1 to about 20 carbon atoms. For instance, an alkyl can have from 1 to 10 carbon atoms or 1 to 5 carbon atoms. Exemplary alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>),</p><p id="p0031" num="0031">-CH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)<sub>3</sub>, -C(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>CH(CH <sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>),</p><p id="p0032" num="0032">-CH<sub>2</sub>CH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>C(CH<sub>2</sub>CH <sub>3</sub>)<sub>3</sub>, -CH(CH<sub>3</sub>)CH(CH <sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>),</p><p id="p0033" num="0033">-CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)(CH<sub>2</sub> CH<sub>3</sub>), -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, </p><p id="p0034" num="0034"> -CH<sub>2</sub>CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, 
<!-- EPO <DP n="6"/>-->
 -CH(CH<sub>3</sub>)CH(CH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, and the like. Thus, alkyl groups include primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups. </p><p id="p0035" num="0035"> The phrase "substituted alkyl" refers to alkyl substituted at one or more positions, for example, 1 , 2, 3, 4, 5, or even 6 positions, which substituents are attached at any available atom to produce a stable compound, with substitution as described herein. "Optionally substituted alkyl" refers to alkyl or substituted alkyl. </p><p id="p0036" num="0036"> "Alkene" refers to straight, branched chain, or cyclic hydrocarbyl groups including from 2 to about 20 carbon atoms having 1-3, 1-2, or at least one carbon to carbon double bond. </p><p id="p0037" num="0037">"Substituted alkene" refers to alkene substituted at 1 or more, e.g., 1 , 2, 3, 4, 5, or even 6 positions, which substituents are attached at any available atom to produce a stable compound, with substitution as described herein. "Optionally substituted alkene" refers to alkene or substituted alkene. The terms "allyl" or "allylene" belongs to the genus "alkene" and refers to a compound having the following generic structure CH2=CH-CH2-. Suitable allylating reagents include without limitation allyl chloride, allyl bromide, allyl iodide, allyl carbonate, allyl alcohol and allyl diphenylphosphine oxide. </p><p id="p0038" num="0038"> The term "alkenylene" refers to divalent alkene. Examples of alkenylene include without limitation, ethenylene (-CH=CH-) and all stereoisomeric and conformational isomeric forms thereof. "Substituted alkenylene" refers to divalent substituted alkene. "Optionally substituted alkenylene" refers to alkenylene or substituted alkenylene. </p><p id="p0039" num="0039"> Each of the terms "halogen," "halide," and "halo" refers to -F, -CI, -Br, or -I. </p><p id="p0040" num="0040"> The term "aryl," alone or in combination refers to an aromatic monocyclic or bicyclic ring system such as phenyl or naphthyl. "Aryl" also includes aromatic ring systems that are optionally fused with a cycloalkyl ring, as herein defined. </p><p id="p0041" num="0041"> A "substituted aryl" is an aryl that is independently substituted with one or more substituents attached at any available atom to produce a stable compound, wherein the substituents are as described herein. "Optionally substituted aryl" refers to aryl or substituted aryl. </p><p id="p0042" num="0042"> "Arylene" denotes divalent aryl, and "substituted arylene" refers to divalent substituted aryl. "Optionally substituted arylene" refers to arylene or substituted arylene. </p><p id="p0043" num="0043"> A "hydroxyl" or "hydroxy" refers to an -OH group. 
<!-- EPO <DP n="7"/>-->
 The term "alkoxy" refers to an -O-alkyl group having the indicated number of carbon atoms. For example, a (Ci-C6)alkoxy group includes -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, - O-butyl, -O-sec-butyl, -O-tert-b tyl, -O-pentyl, -O-isopentyl, -O-neopentyl, -O-hexyl, -O- isohexyl, and -O-neohexyl. </p><p id="p0044" num="0044"> The term<sup>'</sup>"(C3-Ci4)aryl-(C] -C6)alkylene" refers to a divalent alkylene wherein one or more hydrogen atoms in the C 1 -C6 alkylene group is replaced by a (C3-C]4)aryl group. Examples of (C3-Ci<sub>4</sub>)aryl-(Ci-C6)alkylene groups include without limitation 1 -phenylbutylene, phenyl- 2-butylene, l -phenyl-2-methylpropylene, phenylmethylene, phenylpropylene, and naphthylethylene. </p><p id="p0045" num="0045"> The phrase "protecting group" as used herein means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 3<sup>rd</sup> ed.; Wiley: New York, 1999). Suitable alcohol protecting groups are well know in the chemical art, and include without limitation actetyl, benzoyl, benzyl, p-methoxyethoxymethyl ether, mefhoxymefhyl ether, dimethoxytrityl, p-methoxybenzyl ether, trityl, silyl ether (e.g., trimefhylsilyl (TMS), teri-butyldimethylsilyl (TBMDS), ½r/-butyldimethylsilyloxymethyl (TOM) or triisopropylsilyl (TIPS) ether), tetrahydropyranyl (THP), methyl ether and ethoxyethyl ether. </p><p id="p0046" num="0046"> The term "cycloalkyl" refer to monocyclic, bicyclic, tricyclic, or polycyclic, 3- to 14- membered ring systems, which are either saturated, unsaturated or aromatic. The heterocycle may be attached via any atom. Cycloalkyl also contemplates fused rings wherein the cycloalkyl is fused to an aryl or hetroaryl ring as defined above. Representative examples of cycloalkyl include, but are not limited to cyclopropyl, cycloisopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropene, cyclobutene, cyclopentene, cyclohexene, phenyl, naphthyl, anthracyl, benzofuranyl, and benzothiophenyl. A cycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein below. 
<!-- EPO <DP n="8"/>-->
 The term "cycloalkylene" refers to divalent cycloalkylene. The term "optionally substituted cycloalkylene" refers to cycloalkylene that is substituted with 1 to 3 substituents, e.g., 1 , 2 or 3 substituents, attached at any available atom to produce a stable compound, wherein the substituents are as described herein. </p><p id="p0047" num="0047"> The present compounds may exist in various isomeric forms, including configurational, geometric, and conformational isomers, including, for example, cis- or trans- conformations. The present compounds may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers. The term "isomer" is intended to encompass all isomeric forms of a compound of this invention, including tautomeric forms of the compound. All forms are included in the invention. </p><p id="p0048" num="0048"> Some compounds described here may have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. A compound of the invention may be in the form of an optical isomer or a diastereomer. Accordingly, the invention encompasses compounds of the invention and their uses as described herein in the form of their optical isomers, diastereoisomers and mixtures thereof, including a racemic mixture. Optical isomers of the compounds of the invention may be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology or via chemical separation of stereoisomers through the employment of optically active resolving agents. </p><p id="p0049" num="0049"> Unless otherwise indicated, "stereoisomer" means one stereoisomer of a compound that is substantially free of other stereoisomers of that compound. Thus, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, for example greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, or greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other </p><p id="p0050" num="0050">&gt;) 
<!-- EPO <DP n="9"/>-->
 stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound.</p><p id="p0051" num="0051">If there is a discrepancy between a depicted structure and a name given to that structure, then the depicted structure controls. Additionally, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. In some cases, however, where more than one chiral center exists, the structures and names may be represented as single enantiomers to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know if the compounds are prepared as single enantiomers from the methods used to prepare them. </p><p id="p0052" num="0052">Methods for Synthesizing Formula I Compounds </p><p id="p0053" num="0053">The present application relates to a compound according to Formula I and to methods for making Formula I compounds. </p><p id="p0054" num="0054"><img id="imgf000009_0001" he="24" wi="27" file="imgf000009_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0055" num="0055"> For Formula I compounds R may be an alcohol protecting group or R may be selected from the group consisting of H, straight or branched (C] -C6)alkyl, (C6-Ci<sub>4</sub>)aryl and (C6- C i4)aryl(Ci-C6)alkylene-. For example, R may be one of the alcohol protecting groups disclosed above. In some embodiments, R may be selected from the group consisting of actetyl, benzoyl, benzyl, p-methoxyethoxymethyl ether, methoxymethyl ether, </p><p id="p0056" num="0056">dimethoxytrityl, p-methoxybenzyl ether, trityl, silyl ether (e.g., trimethylsilyl (TMS), tert- butyldimethylsilyl (TBMDS), ter^butyldimethylsilyloxymethyl (TOM) or triisopropylsilyl (TIPS) ether), tetrahydropyranyl (THP), methyl ether and ethoxyethyl ether. In some embodiments, R may be methyl, p-methoxybenzyl or benzyl. </p><p id="p0057" num="0057"> Also contemplated is a facile and efficient synthesis for Formula I compounds. Although, synthesis of a Formula I compound by direct allylation of a meta-substituted arylaldehyde which was protected as an imine has been carried out, gas chromatography analysis showed 
<!-- EPO <DP n="10"/>-->
 the obtained product to be a mixture of three components, namely, a Formula I compound and a mixture of its positional regioisomers depicted below as compounds (A) and (B). </p><p id="p0058" num="0058"><img id="imgf000010_0001" he="24" wi="67" file="imgf000010_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0059" num="0059"> While the above process simplified synthesis of a Formula I, the obtained product contained the desired Formula I compound as well as undesired regioisomers. In an attempt to improve yields and eliminate undesired side products, the present inventor undertook a study to develop an alternate methodology for synthesizing a Formula I compound. In one embodiment, therefore, is provided a one pot synthesis for a Formula I compound. </p><p id="p0060" num="0060"> The overall protocol is illustrated in Scheme 1. Synthesis of the target compound according to the inventive process may begin with the in-situ protection of aldehyde (6) using, for example, Ν,Ν,Ν-trimethylethylene diamine in the presence of phenyllithium or butyllithium to give (6a). Ortho-lithiation of the protected aldehyde (6a) may follow conversion of the ortho-lithiated intermediate to the corresponding cuprate (6c), and allylation may give intermediate (6d) which may be hydrolyzed in-situ to afford the target compound (7). As illustrated below, the conversion of lithiated intermediate (6b) to the corresponding cuprate (6c) helps to improve yield by stabilizing the ortho-anion and promoting allylation. 
<!-- EPO <DP n="11"/>-->
</p><p id="p0061" num="0061"><img id="imgf000011_0001" he="98" wi="150" file="imgf000011_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0062" num="0062"> There are several advantages of the present method over previous synthetic processes for making a Formula I compound. For example, the target compound may be synthesized by the direct allylation of an appropriately substituted commercially available aldehyde. </p><p id="p0063" num="0063">Because synthesis is achieved in "one-pot," there is no need to isolate and purify </p><p id="p0064" num="0064">intermediates. Accordingly, the present method may reduce the overall number of synthetic steps, save time and avoid the use of extra chemicals, manpower, and large volume of solvents. Another advantage of the present method may be that it may permit the synthesis to be carried out at ambient temperature (no need for cryogenic equipment), and eliminates tedious column chromatographic purifications. Moreover, the yield and chemical purity of the desired product is greatly improved. </p><p id="p0065" num="0065"> Other differences between the inventive process for ortho-lithiation of aromatic aldehydes and processes disclosed in the prior art (e.g., Comins et al., J. Org. Chem., 1984, 49, 1078 and /. Org. Chem., 1989, 54, 3730), are the stabilization of ortho-lithiated anion intermediate by copper cyanide (3 c, scheme 2), and the use of solvent MTBE in place of THF as the solvent. The present inventor also found allyl iodide to be a better allylating reagent than allyl bromide used in many prior art processes. Based on these initial observations, a study 
<!-- EPO <DP n="12"/>-->
 was undertaken in which the following parameters listed in Table 1 were altered for improving the synthesis of a Formula I compound. </p><p id="p0066" num="0066"><img id="imgf000012_0001" he="79" wi="147" file="imgf000012_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0067" num="0067"> A total of fourteen experiments were carried out to identify experimental parameters that provided the target compound in high yield and purity. The experimental details are set forth in Table 2a - 2c below. 
<!-- EPO <DP n="13"/>-->
</p><p id="p0068" num="0068"><img id="imgf000013_0001" he="209" wi="148" file="imgf000013_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><!-- EPO <DP n="14"/>--><img id="imgf000014_0001" he="104" wi="147" file="imgf000014_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0069" num="0069"> As illustrated from this study, synthesis of a Formula I compound was improved when ortho- lithiation is carried out at a temperature between 30 °C and 35 °C using phenyllithium or butyllithium. Furthermore, the target compound (7) was obtained in good yield and high purity when allylation is carried out at ambient temperatures, for example at room temperature. </p><p id="p0070" num="0070"> The invention is further illustrated by, though in no way limited to, the following examples. Examples </p><p id="p0071" num="0071"> 1. In situ Protection of Aldehyde as Lithium ((2-(dimethylamino) </p><p id="p0072" num="0072"> ethyl(methyl)amino)(3-methoxyphenyl)methanolate (6a) </p><p id="p0073" num="0073">A 500-mL, three-necked, round-bottom flask equipped with a mechanical stirrer and an adapter for bubbling argon was charged with Ν,Ν,Ν-trimethyl ethylenediamine (2.926 g) and MTBE (20 mL) under an inert atmosphere at room temperature. To this solution was added phenyl lithium or n-butyllithium (16 mL or 1 1.5 mL, respectively), and the reaction mixture was stirred at for 15-30 minutes at ambient temperature. A solution of 3- methoxybenza 1 dehyde (3, 3.0 g) in MTBE (5 mL) was then added to the flask over a period 
<!-- EPO <DP n="15"/>-->
 of 10-15 minutes and the reaction mixture was allowed to stir for another 20-30 minutes to generate the titled compound lithium ((2-(dimethylamino)ethyl)(methyl)amino)(3- methoxyphenyl)methanolate (6a), in situ. </p><p id="p0074" num="0074"> 2. AJlylation Reaction </p><p id="p0075" num="0075">To the solution of the protected aldehyde was added phenyl lithium (49 mL, 1.8 M in butyl ether) drop wise over a period of 15-30 minutes. The reaction mixture was heated at 35±2°C for 3-4 hours and then allowed to cool to room temperature. Copper cyanide (8.5g) was then</p><p id="p0076" num="0076">Added and the reaction mixture was stirred for 30-60 minutes at the room temperature. To the resulting suspension was added allyl iodide (9.1 mL) added drop wise over a 20-30 minute interval of time. Following the addition of allyl iodide, the reaction mixture was stirred for an additional 30-60 minutes and the progress of the allylation reaction was monitored by TLC using a mixture of dichloromethane : ethylacetate : hexane (15:85: 15) as the eluting solvent. If needed, TLC plates were eluted more than once to improve resolution.</p><p id="p0077" num="0077">Following completion, the reaction mixture was quenched with sodium sulfite (12 g dissolved in water (30 mL)), followed by the addition of Celite (10-12 g). After stirring the reaction mixture vigorously, it was filtered through a pad of Cel ite, followed by a wash step using ethyl acetate. The organic layer containing the crude was washed with saturated NaHS03 (2x50 mL) solution and concentrated in vacuo. </p><p id="p0078" num="0078"> The obtained crude product was dissolved in ethanol (50 mL). Sodium bisulfate (3.6 g) was added to the ethanolic solution and the mixture was heated at a temperature between 40- 60°C. Water (25 mL) and ethyl acetate (25 mL) were added to during heating to prevent precipitation and keep the reaction mixture clear. </p><p id="p0079" num="0079"> Following heating, the solution is cooled and the solvent removed under reduced pressure to obtain solid material. Tituration of the solid material with hexanes/MTBE (2: 1 solution) removed impurities as judged by TLC. The solid material which is the sodium bisulfite adduct of the target compound (7) was isolated by filtration, dissolved in saturated sodium bicarbonate (50 mL) and extracted with ethyl aceate or MTBE (3x50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to yield compound 7 (2.82 g, 73%). 
<!-- EPO <DP n="16"/>-->
 A similar synthetic strategy (see Scheme 2), was employed to allylate 3-(benzyloxy) benzaldehyde (8). Briefly, protection of the aldehyde using Ν,Ν,Ν-trimethyl </p><p id="p0080" num="0080">ethylenediamine followed by ortho-lithiation and treatment with copper cyanide generates the corresponding cuperate in situ. Allylation of the cooperate using allyl iodide followed by hydrolysis gave the target compound (9) in 70% yield. </p><p id="p0081" num="0081"><img id="imgf000016_0001" he="43" wi="120" file="imgf000016_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0082" num="0082"> Inventive compounds (7) or (9) have been used to synthesize the prostacyclin analog (+)- Treprostinil. </p><p id="p0083" num="0083"> All references and publications cited in the specification are incorporated by reference herein to the same extent as if individually incorporated by reference. </p><p id="p0084" num="0084"> Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such </p><p id="p0085" num="0085">modifications are intended to be within the scope of the present invention. 
</p></description><claims mxw-id="PCLM44851330" ref-ucid="WO-2012118943-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="17"/>-->WHAT IS CLAIMED IS: </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A method for synthesizing a compound according to Formula I, comprising: </claim-text><claim-text> <img id="imgf000017_0001" he="64" wi="93" file="imgf000017_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> wherein </claim-text><claim-text> x is an integer between 0 and 4 inclusive; </claim-text><claim-text> R an alcohol protecting group or is selected from the group consisting of H, straight or branched (Ci-C<sub>6</sub>)alkyl, (C<sub>6</sub>-Ci<sub>4</sub>)aryl, and (C<sub>6</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene-; and </claim-text><claim-text> R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are each independently selected from the group consisting of H, straight or branched (Ci-C<sub>6</sub>)alkyl, (C3-C<sub>6</sub>)cycloalkyl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene- and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl(Ci-C<sub>6</sub>)alkylene-. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The method of claim 1 , further comprising the step of synthesizing the compound of Formula A by: </claim-text><claim-text>(i) contacting a compound of Formula B with an organolithium </claim-text><claim-text> <img id="imgf000017_0002" he="29" wi="45" file="imgf000017_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text>(ii) converting the lithiated product from step (i) to a cuprate using copper cyanide; and </claim-text><claim-text>(iii) contacting the cuprate from step (ii) with an allyl halide selected from the group consisting of allyl chloride, allyl bromide and allyl iodide; <!-- EPO <DP n="18"/>--> wherein, </claim-text><claim-text> x is an integer between 0 and 4 inclusive; </claim-text><claim-text> R is selected from the group consisting of H, straight or branched (Ci-C<sub>6</sub>)alkyl, (C<sub>6</sub>- Ci<sub>4</sub>)aryl and (C<sub>6</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene-; and </claim-text><claim-text> R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are each independently selected from the group consisting of H, straight or branched (Ci-C<sub>6</sub>)alkyl, (C3-C<sub>6</sub>)cycloalkyl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl, (C<sub>3</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene- and (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl(Ci-C<sub>6</sub>)alkylene-. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The method of claim 1, wherein R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are each independently </claim-text><claim-text>(Ci-C<sub>6</sub>)alkyl. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The method of claim 3, wherein R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are methyl. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The method of claim 1, wherein R<sup>a</sup>, is (Ci-C<sub>6</sub>)alkyl and R<sup>b</sup>, R<sup>c</sup> are each independently (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The method of claim 1 , wherein integer x is 2. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The method of claim 1 , wherein R is straight or branched (Ci-C<sub>6</sub>)alkyl. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The method of claim 1 , wherein R is methyl. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The method of claim 1 , wherein R is (C<sub>6</sub>-Ci<sub>4</sub>)aryl(Ci-C<sub>6</sub>)alkylene-. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The method of claim 1 , wherein R is benzyl. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1. The method of claim 2, wherein the organolithium is phenyllithium, or butyllithium. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The method of claim 2, wherein the allyl halide is allyl bromide. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The method of claim 2, wherein the allyl halide is allyl iodide. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The method of claim 1 , wherein said hydro lyzing comprises contacting a compound represented by Formula A with an agent selected from the group consisting of water, aqueous mineral acid and an aqueous solution of sodium sulfite. <!-- EPO <DP n="19"/>--> </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The method of claim 1 , wherein said hydro lyzing comprises contacting a compound represented by Formula A with aqueous solution of sodium sulfite. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>A method for synthesizing a compound according to Formula I, comprising: </claim-text><claim-text> <img id="imgf000019_0001" he="24" wi="26" file="imgf000019_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (a) contacting an aldehyde represented by Formula C </claim-text><claim-text> <img id="imgf000019_0002" he="25" wi="25" file="imgf000019_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> with a compound selected from the group consisting of R<sup>a</sup>-NH<sub>2</sub>, R<sup>a</sup>R<sup>b</sup>N-(CHR')<sub>x</sub>-NHR<sup>a</sup> and R'-OH in the presence of an organolitium; </claim-text><claim-text> (b) contacting the product from step (a) with an organolithium to form an ortho-lithiated product, and then contacting the ortho-lithiated product with copper cyanide to form a cuprate; </claim-text><claim-text> (c) contacting the cuprate from step (b) with an allyl halide selected from the group consisting of allyl chloride, allyl bromide and allyl iodide; and </claim-text><claim-text> (c) hydrolyzing the product of step (c) to give the Formula I compound. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The method of claim 16, wherein said organolithium is phenyllithium. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The method of claim 16, wherein in step (a) the aldehyde of Formula C is contacted with R<sup>a</sup>R<sup>b</sup>N-(CHR')<sub>x</sub>-NHR<sup>a</sup>. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The method of claim 18, wherein integer x is 2 and R<sup>a</sup>, R<sup>b</sup> and R<sup>c</sup> are methyl. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The method of claim 16, wherein the allyl halide is allyl iodide. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
